Literature DB >> 11747273

Detection of occult metastasis in patients with breast cancer.

D Hawes1, A M Neville, R J Cote.   

Abstract

The most important factor affecting the outcome of patients with invasive cancer is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary "curative" therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by routinely employed methods (careful pathological, clinical, biochemical, and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11747273     DOI: 10.1002/ssu.1049

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  3 in total

Review 1.  The detection of circulating breast cancer cells in blood.

Authors:  A M Gilbey; D Burnett; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

2.  Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.

Authors:  Shinkichi Sato; Masaya Mukai
Journal:  Diagn Pathol       Date:  2010-02-24       Impact factor: 2.644

3.  Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.

Authors:  Q Chen; L Yao; D Burner; B Minev; L Lu; M Wang; W Ma
Journal:  Clin Transl Oncol       Date:  2018-09-14       Impact factor: 3.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.